The risk of being unable to reliably generate new drug candidates or an R&D pipeline despite pursuing partnerships with academia and biotech companies, building networks, and introducing technologies. Unlike delays or discontinuation in the clinical development of existing candidates or failure to achieve results from R&D investment overall, this risk covers the process from discovery and seed acquisition through the formation of a new pipeline.